RNAZ Transcode Therapeutics Inc

Price (delayed)

$5.88

Market cap

$5.59M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$50.33

Enterprise value

-$7.25M

Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 0
Highlights
The EPS has soared by 95% YoY and by 4.3% QoQ
Transcode Therapeutics's equity has plunged by 88% from the previous quarter and by 88% YoY
Transcode Therapeutics's net income has plunged by 58% YoY and by 16% from the previous quarter

Key stats

What are the main financial stats of RNAZ

RNAZ stock price

How has the Transcode Therapeutics stock price performed over time
Intraday
16.67%
1 week
11.15%
1 month
-24.03%
1 year
-20.43%
YTD
-13.91%
QTD
-31.71%

Financial performance

How have Transcode Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$42.56M
Net income
-$40.36M
Gross margin
N/A
Net margin
N/A
The company's operating income has shrunk by 174% YoY and by 52% QoQ
Transcode Therapeutics's net income has plunged by 58% YoY and by 16% from the previous quarter

Price vs fundamentals

How does RNAZ's price correlate with its fundamentals

Growth

What is Transcode Therapeutics's growth rate over time

Valuation

What is Transcode Therapeutics stock price valuation
P/E
N/A
P/B
4.31
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has soared by 95% YoY and by 4.3% QoQ
Transcode Therapeutics's equity has plunged by 88% from the previous quarter and by 88% YoY
The price to book (P/B) is 54% higher than the 5-year quarterly average of 2.4 and 2.5% higher than the last 4 quarters average of 3.6

Efficiency

How efficient is Transcode Therapeutics business performance
The company's return on assets has surged by 85% YoY and by 32% QoQ
The company's return on equity has shrunk by 77% QoQ

Dividends

What is RNAZ's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for RNAZ.

Financial health

How did Transcode Therapeutics financials performed over time
The quick ratio has plunged by 55% from the previous quarter and by 50% YoY
The current ratio has plunged by 51% from the previous quarter and by 40% YoY
Transcode Therapeutics's debt is 100% less than its equity
Transcode Therapeutics's equity has plunged by 88% from the previous quarter and by 88% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.